Skip to main content
Top
Published in: Clinical and Experimental Nephrology 4/2018

01-08-2018 | Original Article

Inverse correlation between left ventricular end-diastolic pressure and contrast-induced nephropathy in patients undergoing percutaneous coronary intervention

Authors: Guoqiang Gu, Hanghang Xing, Yaqing Zhou, Wei Cui

Published in: Clinical and Experimental Nephrology | Issue 4/2018

Login to get access

Abstract

Background

There is a rising incidence of contrast-induced nephropathy (CIN), which is defined as either a 25% relative increase or an absolute increase of 0.5 mg/dL (44.2 µmol/L) in the serum creatinine (Scr) level at 48–72 h after administration of iodinated contrast media (CM). We investigated the relationship between left ventricular end-diastolic pressure (LVEDP) and CIN in patients undergoing percutaneous coronary intervention (PCI).

Methods

A total of 431 consecutive patients with coronary artery disease undergoing PCI were divided into four groups based on LVEDP quartile cut-off points. Enrolled patients were given continuous intravenous infusion of normal saline starting 4 h before PCI and lasting 24 h. At the end of hydration administration, 20 mg furosemide was slowly injected intravenously. Serum creatinine (Scr), creatinine clearance rate (Ccr), and glomerular filtration rate (GFR) were detected before and after PCI.

Results

There were significant differences in the incidences of CIN in the four groups: 10.25% in the Q1 group, 5.55% in the Q2 group, 5.31% in the Q3 group, and 1.06% in the Q4 group (P < 0.05). With increasing LVEDP, the incidence of CIN decreased significantly (OR 0.581, 95% CI 0.367–0.920). Received operating characteristic curve analysis of the predictive value of LVEDP for CIN produced area under the curve values was 0.641, with a sensitivity of 74.1% and specificity of 48%. The optimal LVEDP cut-off for the occurrence of CIN was 14.5 mmHg.

Conclusions

LVEDP correlated inversely with CIN in patients undergoing PCI.
Literature
1.
go back to reference Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol. 1999;9(8):1602–13.CrossRefPubMed Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol. 1999;9(8):1602–13.CrossRefPubMed
2.
go back to reference Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930–6.CrossRefPubMed Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5):930–6.CrossRefPubMed
3.
go back to reference Jorgensen AL. Contrast-induced nephropathy: pathophysiology and preventive strategies. Crit Care Nurse. 2013;33(1):37–46.CrossRefPubMed Jorgensen AL. Contrast-induced nephropathy: pathophysiology and preventive strategies. Crit Care Nurse. 2013;33(1):37–46.CrossRefPubMed
4.
go back to reference Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–9.PubMed Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–9.PubMed
5.
go back to reference Ohno I, Hayashi H, Aonuma K, Horio M, Kashihara N, Okada H, et al. Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version: JSN, JRS, and JCS Joint Working Group. Clin Exp Nephrol. 2013;17(4):441–79.CrossRefPubMed Ohno I, Hayashi H, Aonuma K, Horio M, Kashihara N, Okada H, et al. Guidelines on the use of iodinated contrast media in patients with kidney disease 2012: digest version: JSN, JRS, and JCS Joint Working Group. Clin Exp Nephrol. 2013;17(4):441–79.CrossRefPubMed
6.
go back to reference Weisbord SD, Palevsky PM. Prevention of contrast-induced nephropathy with volume expansion. Clin J Am Soc Nephrol. 2008;3(1):273–80.CrossRefPubMed Weisbord SD, Palevsky PM. Prevention of contrast-induced nephropathy with volume expansion. Clin J Am Soc Nephrol. 2008;3(1):273–80.CrossRefPubMed
7.
go back to reference Chen H, Lin G, Wang J. Practice of internal medicine, 14th ed. People’s Medical Publishing House; 2013;249:275. Chen H, Lin G, Wang J. Practice of internal medicine, 14th ed. People’s Medical Publishing House; 2013;249:275.
8.
go back to reference Mao H, Cao L. Cardiology, 2nd edn. Shelton:People’s Medical Publishing House; 2001, pp 410–13 Mao H, Cao L. Cardiology, 2nd edn. Shelton:People’s Medical Publishing House; 2001, pp 410–13
9.
go back to reference He YT, Tan N, Liu YH, Chen SQ, Liu Y, Huang SJ, et al. Association between high-sensitivity C-reactive protein and contrast-induced nephropathy after primary percutaneous coronary intervention. Zhonghua Xin Xue Guan Bing Za Zhi. 2013;41(5):394–8.PubMed He YT, Tan N, Liu YH, Chen SQ, Liu Y, Huang SJ, et al. Association between high-sensitivity C-reactive protein and contrast-induced nephropathy after primary percutaneous coronary intervention. Zhonghua Xin Xue Guan Bing Za Zhi. 2013;41(5):394–8.PubMed
10.
go back to reference Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008;300(9):1038–46.CrossRefPubMed Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA. 2008;300(9):1038–46.CrossRefPubMed
11.
go back to reference Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. JACC Cardiovasc Interv. 2012;5(1):90–7.CrossRefPubMed Marenzi G, Ferrari C, Marana I, Assanelli E, De Metrio M, Teruzzi G, et al. Prevention of contrast nephropathy by furosemide with matched hydration: the MYTHOS (Induced Diuresis With Matched Hydration Compared to Standard Hydration for Contrast Induced Nephropathy Prevention) trial. JACC Cardiovasc Interv. 2012;5(1):90–7.CrossRefPubMed
12.
go back to reference Gu GQ, Lu R, Cui W, Liu F, Zhang Y, Yang XH, et al. Low-dose furosemide administered with adequate hydration reduces contrast-induced nephropathy in patients undergoing coronary angiography. Cardiology. 2013;125(2):69–73.CrossRefPubMed Gu GQ, Lu R, Cui W, Liu F, Zhang Y, Yang XH, et al. Low-dose furosemide administered with adequate hydration reduces contrast-induced nephropathy in patients undergoing coronary angiography. Cardiology. 2013;125(2):69–73.CrossRefPubMed
13.
go back to reference Putzu A, Boscolo Berto M, Belletti A, Pasotti E, Cassina T, Moccetti T, et al. Prevention of contrast-induced acute kidney injury by furosemide with matched hydration in patients undergoing interventional procedures: a systematic review and meta-analysis of randomized trials. JACC Cardiovasc Interv. 2017;10(4):355–63.CrossRefPubMed Putzu A, Boscolo Berto M, Belletti A, Pasotti E, Cassina T, Moccetti T, et al. Prevention of contrast-induced acute kidney injury by furosemide with matched hydration in patients undergoing interventional procedures: a systematic review and meta-analysis of randomized trials. JACC Cardiovasc Interv. 2017;10(4):355–63.CrossRefPubMed
Metadata
Title
Inverse correlation between left ventricular end-diastolic pressure and contrast-induced nephropathy in patients undergoing percutaneous coronary intervention
Authors
Guoqiang Gu
Hanghang Xing
Yaqing Zhou
Wei Cui
Publication date
01-08-2018
Publisher
Springer Singapore
Published in
Clinical and Experimental Nephrology / Issue 4/2018
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-017-1514-6

Other articles of this Issue 4/2018

Clinical and Experimental Nephrology 4/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.